<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39352656</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1678-4405</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]</Title><ISOAbbreviation>Braz J Microbiol</ISOAbbreviation></Journal><ArticleTitle>Prevalence and molecular characterization of carbapenem-resistant Enterobacterales in patients from a public referral hospital in a non-metropolitan region of Brazil during and post the SARS-CoV-2 pandemic.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s42770-024-01531-7</ELocationID><Abstract><AbstractText>Antimicrobial resistance (AMR) poses a global threat, with carbapenem-resistant Enterobacterales (CRE) representing a significant concern due to limited therapeutic options. This study investigated the prevalence of carbapenemase genes in CRE strains isolated from tracheal aspirates of patients at a Brazilian university hospital between January 2020 and August 2023. Bacterial identification was conducted using MALDI-TOF, while carbapenemase genes were detected by qPCR. Demographic and clinical data were collected, and univariate analysis was performed using the chi-square test (p &lt; 0.05). Variables with p ≤ 0.10 were further investigated using the chi-square test for linear trend, along with stratified analysis. Out of 1,133 samples, 111 (9.79%) showed CRE growth, with 46 isolates included in the final sample, predominantly comprising Klebsiella pneumoniae (65.21%) and Serratia marcescens (19.57%). The bla<sub>KPC</sub> gene was prevalent (78.26%), while bla<sub>NDM</sub> was detected in 21.74% of cases. The identified population was predominantly male (67.39%), elderly (69.57%), white (56.52%), unmarried (63.04%), and had a low level of education (56.52%). Most patients (69.57%) were in the intensive care unit and remained hospitalized for more than 30 days (76.08%). There was a significant inverse trend between Klebsiella pneumoniae and age (p = 0.045), as well as a direct linear trend between bla<sub>NDM</sub> and the annual increase in COVID-19 cases in Brazil (p = 0.050). A high probability of finding non-Klebsiella pneumoniae bacteria was observed in patients with prolonged hospital stays, independent of COVID-19 (p = 0.006) and the type of resistance genes (p = 0.020). The persistent prevalence of CRE, especially with bla<sub>KPC</sub>, underscores the urgency of effective control measures.</AbstractText><CopyrightInformation>© 2024. The Author(s) under exclusive licence to Sociedade Brasileira de Microbiologia.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fochat</LastName><ForeName>Romário Costa</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Postgraduate Program in Collective Health, Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Biology Laboratory, College of Pharmacy, Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Lelis Araújo</LastName><ForeName>Ana Clara</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Molecular Biology Laboratory, College of Pharmacy, Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pereira Júnior</LastName><ForeName>Olavo Dos Santos</ForeName><Initials>ODS</Initials><AffiliationInfo><Affiliation>Molecular Biology Laboratory, College of Pharmacy, Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy, Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silvério</LastName><ForeName>Marcelo Silva</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Molecular Biology Laboratory, College of Pharmacy, Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy, Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nassar</LastName><ForeName>Alessandra Figueiredo de Castro</ForeName><Initials>AFC</Initials><AffiliationInfo><Affiliation>Instituto Biológico, Center for Research in Animal Health, São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Junqueira</LastName><ForeName>Maria de Lourdes</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Federal University of Juiz de Fora, University Hospital, Juiz de Fora, Minas Gerais, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Marcio Roberto</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Postgraduate Program in Collective Health, Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Embrapa Dairy Cattle, Brazilian Agricultural Research Company, Juiz de Fora, Minas Gerais, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia</LastName><ForeName>Patrícia Guedes</ForeName><Initials>PG</Initials><Identifier Source="ORCID">0000-0002-0795-6422</Identifier><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy, Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil. patricia.guedes@ufjf.br.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Braz J Microbiol</MedlineTA><NlmUniqueID>101095924</NlmUniqueID><ISSNLinking>1517-8382</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Klebsiella pneumoniae</Keyword><Keyword MajorTopicYN="N">Serratia marcescens</Keyword><Keyword MajorTopicYN="N">bla KPC</Keyword><Keyword MajorTopicYN="N">bla NDM</Keyword><Keyword MajorTopicYN="N">Antimicrobial resistance</Keyword><Keyword MajorTopicYN="N">Tracheal aspirate</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>11</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39352656</ArticleId><ArticleId IdType="doi">10.1007/s42770-024-01531-7</ArticleId><ArticleId IdType="pii">10.1007/s42770-024-01531-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Centers for Disease Control and Prevention [CDC] (2019) Antibiotic resistance threats in the United States, 2019. Atlanta, GA: United States Department of Health and Human Services. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf . Accessed 08 April 2024</Citation></Reference><Reference><Citation>World Health Organization [WHO] (2019) Top ten threats to global health in 2019. Geneva: World Health Organization. https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019 . Accessed 08 April 2024</Citation></Reference><Reference><Citation>O’Neill J (2014) Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations. The Review on Antimicrobial Resistance Chaired by Jim O’Neill. Review on Antimicrobial Resistance. Wellcome Trust. HM Government. https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf . Accessed 08 April 2024</Citation></Reference><Reference><Citation>World Health Organization [WHO], Food and Agriculture Organization of the United Nations [FAO], United Nations Environment Programme [UNEP] and World Organisation for Animal Health [WOAH] (2023) A one health priority research agenda for antimicrobial resistance. Geneva: World Health Organization, Food and Agriculture Organization of the United Nations, United Nations Environment Programme and World Organisation for Animal Health. https://iris.who.int/bitstream/handle/10665/370279/9789240075924-eng.pdf?sequence=1 . Accessed 08 April 2024</Citation></Reference><Reference><Citation>Agência Nacional de Vigilância Sanitária [ANVISA] (2023) Pan-Serviços de Saúde: Plano Nacional para prevenção e controle da resistência aos antimicrobianos em serviços de saúde 2023–2027. Brasília: Gerência de Vigilância e Monitoramento em Serviços de Saúde, Gerência Geral de Tecnologia em Serviços de Saúde, Terceira Diretoria, Agência Nacional de Vigilância Sanitária. file:///C:/Users/Usuario/Downloads/pan-servicos-de-saude-2023-2027-final-15-12-2023%20(2).pdf. Accessed 08 April 2024</Citation></Reference><Reference><Citation>Rehman S (2023) A parallel and silent emerging pandemic: antimicrobial resistance (AMR) amid COVID-19 pandemic. J Infect Public Health 16(4):611–617</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2023.02.021</ArticleId><ArticleId IdType="pubmed">36857834</ArticleId><ArticleId IdType="pmc">9942450</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawson TM, Moore LSP, Zhu N et al (2020) Bacterial and fungal co-infection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis 71(9):2459–2468</Citation><ArticleIdList><ArticleId IdType="pubmed">32358954</ArticleId></ArticleIdList></Reference><Reference><Citation>Witt LS, Howard-Anderson JR, Jacob JT et al (2023) The impact of COVID-19 on multidrug-resistant organisms causing healthcare-associated infections: a narrative review. JAC Antimicrob Resist 5(1):1–9</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention [CDC] (2022) COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022. Atlanta, GA: United States Department of Health and Human Services. https://www.cdc.gov/drugresistance/pdf/covid19-impact-report-508.pdf . Accessed 08 April 2024</Citation></Reference><Reference><Citation>Thomas GR, Corso A, Pasterán F et al (2022) Increased detection of carbapenemase-producing enterobacterales bacteria in Latin America and the Caribbean during the COVID-19 pandemic. Emerg Infect Dis 28(11):e220415</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2811.220415</ArticleId><ArticleId IdType="pubmed">36286547</ArticleId><ArticleId IdType="pmc">9622262</ArticleId></ArticleIdList></Reference><Reference><Citation>Fakih MG, Bufalino A, Sturm L et al (2022) Coronavirus disease 2019 (COVID-19) pandemic, central-line–associated bloodstream infection (CLABSI), and catheter-associated urinary tract infection (CAUTI): the urgent need to refocus on hardwiring prevention efforts. Infect Control Hosp Epidemiol 43(1):26–31</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/ice.2021.70</ArticleId><ArticleId IdType="pubmed">33602361</ArticleId></ArticleIdList></Reference><Reference><Citation>Suay-García B, Pérez-Gracia MT (2019) Present and future of carbapenem-resistant Enterobacteriaceae (CRE) infections. Antibiotics 8(3):122</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics8030122</ArticleId><ArticleId IdType="pubmed">31430964</ArticleId><ArticleId IdType="pmc">6784177</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Gamal MI, Brahim I, Hisham N et al (2017) Recent updates of carbapenem antibiotics. Eur J Med Chem 131:185–195</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2017.03.022</ArticleId><ArticleId IdType="pubmed">28324783</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization [WHO] (2024) WHO publishes list of bacteria for which new antibiotics are urgently needed. WHO Bacterial Priority Pathogens List, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Geneva: World Health Organization. https://iris.who.int/bitstream/handle/10665/376776/9789240093461-eng.pdf?sequence=1 Accessed 16 August 2024</Citation></Reference><Reference><Citation>Empresa Brasileira de Serviços Hospitalares [EBSERH], University Hospital of the Federal University of Juiz de Fora [HU-UFJF] (2022) HU-UFJF report 2019 to July 2022. Juiz de Fora: University Hospital of the Federal University of Juiz de Fora. Anexo_Resolução-27.2023-Consu-UFJF_SEI_Assinada.pdf_Relatório_de_Gestão.Monitoramento.pdf. Accessed 08 April 2024</Citation></Reference><Reference><Citation>Kalil AC, Metersky ML, Klompas M et al (2016) Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 63(5):61–111</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciw353</ArticleId></ArticleIdList></Reference><Reference><Citation>Agência Nacional de Vigilância Sanitária [ANVISA] (2004) Manual de Microbiologia Clínica para o controle de infecção em Serviços de Saúde. Brasília: Agência Nacional de Vigilância Sanitária. https://bvsms.saude.gov.br/bvs/publicacoes/manual_microbiologia_completo.pdf . Accessed 08 April 2024</Citation></Reference><Reference><Citation>OPLUSTIL CP, Zoccoli CM, Tobouti NR, Scheffer MC (2020) Procedimentos básicos em Microbiologia Clínica, 4rd edn. Sarvier, São Paulo</Citation></Reference><Reference><Citation>Winn WC, Allen SD, Janda MW et al (2018) Koneman, Diagnóstico Microbiológico: texto e atlas colorido, 7rd edn. Guanabara Koogan, Rio de Janeiro</Citation></Reference><Reference><Citation>Brazilian Committee on Antimicrobial Susceptibility Testing [BrCast] (2023) Cutoff point tables for interpreting MICs and halo diameters. Rio de Janeiro: BrCast. https://www.eucast.org/clinical_breakpoints Accessed 08 April 2024</Citation></Reference><Reference><Citation>Bier D, Tutija JF, Pasquatti TN et al (2017) Identificação por espectrometria de massa MALDI-TOF de Salmonella spp. E Escherichia coli isolados de carcaças bovinas. Pesq Vet Bras 37(12):1373–1379</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/s0100-736x2017001200003</ArticleId></ArticleIdList></Reference><Reference><Citation>VIASURE Real Time PCR Detection Kit (2024) Carbapenemase-producing Enterobacteriaceae. Zaragoza (Spain): Certest Biotec. https://www.certest.es/wp-content/uploads/2021/08/VIASURE_Carbapenemase_EN.pdf . Accessed 08 April 2024</Citation></Reference><Reference><Citation>Gimeno SGA, Souza JMP (1995) Utilização De estratificação E modelo de regressão logística na análise de dados de estudos caso-controle. Rev Saúde Pública 29(4):283–289</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S0034-89101995000400005</ArticleId><ArticleId IdType="pubmed">8729278</ArticleId></ArticleIdList></Reference><Reference><Citation>Sergeant ESG (2018) Epitools Epidemiological Calculators. Ausvet. http://epitools.ausvet.com.au . Accessed 06 April 2024</Citation></Reference><Reference><Citation>Ministério da Saúde (2024) COVID-19 no Brasil. Brasília: Ministério da Saúde. Secretarias Estaduais de Saúde, Dados até 27/01/2024. https://infoms.saude.gov.br/extensions/covid-19_html/covid-19_html.html . Accessed 08 April 2024</Citation></Reference><Reference><Citation>Blot S, Ruppé E, Harbarth S et al (2022) Healthcare-associated infections in adult intensive care unit patients: changes in epidemiology, diagnosis, prevention and contributions of new technologies. Intensive Crit Care Nurs 70(103227):1–15</Citation></Reference><Reference><Citation>Evans ME, Simbartl LA, Kralovic SM et al (2023) Healthcare-associated infections in Veterans affairs acute-care and long-term healthcare facilities during the coronavirus disease 2019 (COVID-19) pandemic. Infect Control Hosp Epidemiol 44(3):420–426</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/ice.2022.93</ArticleId><ArticleId IdType="pubmed">35379366</ArticleId></ArticleIdList></Reference><Reference><Citation>Lastinger LM, Alvarez CR, Kofman A et al (2023) Continued increases in the incidence of healthcare-associated infection (HAI) during the second year of the coronavirus disease 2019 (COVID-19) pandemic. Infect Control Hosp Epidemiol 44(6):997–1001</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/ice.2022.116</ArticleId><ArticleId IdType="pubmed">35591782</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M, Higginson E, Pereira-Dias J et al (2021) Ventilator-associated pneumonia in critically ill patients with COVID-19. Crit Care 25(25):1–11</Citation></Reference><Reference><Citation>Rouzé A, Martin-Loeches I, Povoa P et al (2021) Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study. Intensive Care Med 47(2):188–198</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-06323-9</ArticleId><ArticleId IdType="pubmed">33388794</ArticleId><ArticleId IdType="pmc">7778569</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray AK (2020) The novel coronavirus COVID-19 outbreak: global implications for antimicrobial resistance. Front Microbiol 11(1020):1–4</Citation></Reference><Reference><Citation>Porreca AM, Sullivan KV, Gallagher JC (2018) The epidemiology, evolution, and treatment of KPC-producing organisms. Curr Infect Dis Rep 20(13):1–12</Citation></Reference><Reference><Citation>Logan LK, Weinstein RA (2017) The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis 215(suppl1):28–36</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw282</ArticleId></ArticleIdList></Reference><Reference><Citation>Conceição-Neto OC, Costa BS, Pontes LS et al (2022) Polymyxin resistance in clinical isolates of K. pneumoniae in Brazil: update on molecular mechanisms, clonal dissemination and relationship with KPC-producing strains. Front Cell Infect Microbiol 12(898125):1–13</Citation></Reference><Reference><Citation>Braun G, Cayô R, Matos AP et al (2018) Temporal evolution of polymyxin B– resistant Klebsiella pneumoniae clones recovered from blood cultures in a teaching hospital during a 7-year period. Int J Antimicrob Agents 51(3):522–527</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2017.08.031</ArticleId><ArticleId IdType="pubmed">28887199</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampaio JLM, Gales AC (2016) Antimicrobial resistance in Enterobacteriaceae in Brazil: focus on β-lactams and polymyxins. Braz J Microbiol 47(Suppl 1):31–37</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bjm.2016.10.002</ArticleId><ArticleId IdType="pubmed">27825605</ArticleId><ArticleId IdType="pmc">5156504</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbolleti F, Seco BMS, Santos CC et al (2016) Polymyxin B resistance in carbapenem-resistant Klebsiella pneumoniae, São Paulo, Brazil. Emerg Infect Dis 22(10):1849–1851</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2210.160695</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiffer CRV, Rezende TFT, Costa-Nobre DT et al (2023) A 7-year brazilian national perspective on plasmid-mediated carbapenem resistance in Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii complex and the impact of the coronavirus disease 2019 pandemic on their occurrence. Clin Infect Dis 77(Suppl 1):29–37</Citation></Reference><Reference><Citation>Tuon FF, Cordova K, Dario TM et al (2017) Klebsiella pneumoniae carbapenemase-producing Serratia marcescens outbreak in a university hospital. Am J Infect Control 45(6):700–702</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajic.2017.03.002</ArticleId><ArticleId IdType="pubmed">28431850</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvim ALS, Couto BRGM, Gazzinelli A (2019) Epidemiological profile of healthcare-associated infections caused by carbapenemase-producing Enterobacteriaceae. Rev Esc Enferm USP 53(e03474):1–6</Citation></Reference><Reference><Citation>Lorenzoni VV, Silva DC, Rampelotto RF et al (2017) Evaluation of carbapenem-resistant Enterobacteriaceae in a tertiary-level reference hospital in Rio Grande do sul, Brazil. Rev Soc Bras Med Trop 50(5):685–688</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/0037-8682-0209-2017</ArticleId><ArticleId IdType="pubmed">29160518</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiesh BM, Maali Y, Qandeel F et al (2023) Epidemiology and clinical characteristics of patients with carbapenem-resistant enterobacterales infections: experience from a large tertiary care center in a developing country. BMC Infect Dis 23(644):1–10</Citation></Reference><Reference><Citation>Ahn JY, Ahn SM, Kim JH et al (2023) Clinical characteristics and associated factors for mortality in patients with carbapenem-resistant Enterobacteriaceae bloods tream infection. Microorganisms 11(5):1121</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms11051121</ArticleId><ArticleId IdType="pubmed">37317095</ArticleId><ArticleId IdType="pmc">10220897</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdul-Mutakabbir JC, Griffith NC, Shields RK et al (2021) Contemporary perspective on the treatment of Acinetobacter baumannii infections: insights from the Society of Infectious diseases pharmacists. Infect Dis Ther 10(4):2177–2202</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-021-00541-4</ArticleId><ArticleId IdType="pubmed">34648177</ArticleId><ArticleId IdType="pmc">8514811</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin A, Fahrbach K, Zhao Q et al (2018) Association between carbapenem resistance and mortality among adult, hospitalized patients with serious infections due to Enterobacteriaceae: results of a systematic literature review and meta-analysis. Open Forum Infect Dis 5(7):1–9</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofy150</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>